Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
06-08 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
06-08 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
05 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-poster-presentations-at-digestive-disease-week-ddw-2025-including-up-to-eight-months-of-follow-up-from-an-ongoing-phase-1-trial-of-spy001-302445258.html
27 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-first-participant-dosed-in-phase-1-trial-of-spy003-its-novel-half-life-extended-il-23-antibody-302413345.html
19 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-poster-presentation-at-the-20th-congress-of-the-european-crohns-and-colitis-organisation-302379930.html
13 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spyre-therapeutics-highlights-2025-priorities-and-robust-pipeline-of-upcoming-clinical-readouts-302348969.html
02 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-first-participants-dosed-in-phase-1-trials-of-novel-half-life-extended-anti-tl1a-antibodies-302319340.html
12 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-positive-interim-results-from-phase-1-healthy-volunteer-trial-for-spy001-its-novel-half-life-extended-anti-47-antibody-for-the-treatment-of-inflammatory-bowel-disease-with-a-half-life-of-90-days-s-302302014.html
ABOUT THIS PAGE